Previous 10 | Next 10 |
At three years, new data showed overall survival and disease-free survival of 63% and 56% respectively At ten years, follow-up data demonstrated sustained long-term bone marrow recovery Omidubicel patients reported clinically meaningful health-related quality of life s...
Gamida Cell ( NASDAQ: GMDA ) said it signed a commitment letter under which certain funds managed by Highbridge Capital Management committed to provide a $25M senior secured, convertible term loan to the company. The letter does not represent a definitive credit facili...
Gamida Cell ( NASDAQ: GMDA ) has priced a follow-on public offering of 12.91M of its ordinary shares at a public offering price of $1.55/share for aggregate gross proceeds of $20M. Underwriters are granted a 30-day option to purchase up to an additional 1,935,750 ordinary ...
Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced that it has entered into a Commitment Letter with certain funds managed by Highbridge Capital Man...
Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the pricing of a follow-on public offering of 12,905,000 of its ordinary shares at a public off...
Gamida Cell ( NASDAQ: GMDA ) has launched a follow-on public offering of its shares on Tuesday that is to grant underwriters an overallotment option to purchase an additional 15% of the offering. The Israel-based development stage biopharma firm said it intends t...
Gamida Cell Ltd ( NASDAQ: GMDA ), a biotech focused on cell therapies, announced Monday that Abigail L. Jenkins, who formerly served as the Business Unit Head of Vaccines at contract manufacturer Emergent BioSolutions ( EBS ), has joined the company as Chief Executive. ...
Julian Adams, Ph.D., to Retire and Remain on the Board as Planned Succession Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced th...
- Patients treated with omidubicel reported higher health-related quality of life scores during first-year post-transplant as compared to transplantation with umbilical cord blood (UCB) - If approved, Omidubicel is projected to have meaningful improvement in patient outcom...
Today, we circle back on Gamida Cell Ltd., a small developmental company based in Israel for the first time since last November. The company has a key FDA approval pending which could shift the trajectory of the company and the stock. An investment analysis follows in the paragrap...
News, Short Squeeze, Breakout and More Instantly...
Gamida Cell Ltd. Company Name:
GMDA Stock Symbol:
NASDAQ Market:
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney d...
2024-04-03 06:21:00 ET How to Analyze Different Penny Stocks Sectors to Make Money Investing in penny stocks offers an accessible entry point for individuals aiming to participate in the stock market with a lower initial investment. Analyzing different sectors within the realm of penn...
A look at the top 10 most actives in the United States Trio Petroleum Corp. (TPET) rose 43.8% to $0.1485 on volume of 202,621,744 shares Nikola Corporation (NKLA) fell 5.5% to $0.9736 on volume of 187,304,976 shares C3is Inc. (CISS) rose 13.3% to $0.0409 on volume of 136,767,990 shares ...